{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T03:42:56Z","timestamp":1768016576792,"version":"3.49.0"},"reference-count":96,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["FP7-HEALTH-2013-INNOVATION-1 602570-2 and H2020-SC1-2016-2017"],"award-info":[{"award-number":["FP7-HEALTH-2013-INNOVATION-1 602570-2 and H2020-SC1-2016-2017"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Spanish Ministry of Economy (MINECO)","award":["SAF2015-66193-R and RTI2018-096309-B-I00"],"award-info":[{"award-number":["SAF2015-66193-R and RTI2018-096309-B-I00"]}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["COV20\/00214 and ICI20\/00067"],"award-info":[{"award-number":["COV20\/00214 and ICI20\/00067"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CERCA Programme \/ Generalitat de Catalunya","award":["SGR 615 and SGR 653"],"award-info":[{"award-number":["SGR 615 and SGR 653"]}]},{"name":"Fondo de Investigaci\u00f3n Sanitaria (FIS)","award":["AC16\/00051 and PI18\/00699"],"award-info":[{"award-number":["AC16\/00051 and PI18\/00699"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Over 36 million people worldwide are infected with HIV. Antiretroviral therapy (ART) has proven to be highly effective to prevent HIV-1 transmission, clinical progression and death. Despite this success, the number of HIV-1 infected individuals continues increasing and ART should be taken for life. Therefore, there are two main priorities: the development of preventive vaccines to protect from HIV acquisition and achieve an efficient control of HIV infection in the absence of ART (functional cure). In this sense, in the last few years, there has been a broad interest in new and innovative approaches such as mRNA-based vaccines. RNA-based immunogens represent a promising alternative to conventional vaccines because of their high potency, capacity for rapid development and potential for low-cost manufacture and safe administration. Some mRNA-based vaccines platforms against infectious diseases have demonstrated encouraging results in animal models and humans. However, their application is still limited because the instability and inefficient in vivo delivery of mRNA. Immunogens, design, immunogenicity, chemical modifications on the molecule or the vaccine delivery methods are all crucial interventions for improvement. In this review we, will present the current knowledge and challenges in this research field. mRNA vaccines hold great promises as part of a combined strategy, for achieving HIV functional cure.<\/jats:p>","DOI":"10.3390\/v13030501","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T22:19:36Z","timestamp":1616105976000},"page":"501","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["In the Era of mRNA Vaccines, Is There Any Hope for HIV Functional Cure?"],"prefix":"10.3390","volume":"13","author":[{"given":"Ignasi","family":"Esteban","sequence":"first","affiliation":[{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Pastor-Qui\u00f1ones","sequence":"additional","affiliation":[{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"Usero","sequence":"additional","affiliation":[{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Plana","sequence":"additional","affiliation":[{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7658-5832","authenticated-orcid":false,"given":"Felipe","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain"},{"name":"Infectious Diseases Department, Hospital Cl\u00ednic, University of Barcelona, 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7887-6027","authenticated-orcid":false,"given":"Lorna","family":"Leal","sequence":"additional","affiliation":[{"name":"Institut d\u2019Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain"},{"name":"Infectious Diseases Department, Hospital Cl\u00ednic, University of Barcelona, 08036 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nm880","article-title":"Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells","volume":"9","author":"Siliciano","year":"2003","journal-title":"Nat. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"8454","DOI":"10.1128\/JVI.00163-16","article-title":"Reversion of Cold-Adapted Live Attenuated Influenza Vaccine into a Pathogenic Virus","volume":"90","author":"Zhou","year":"2016","journal-title":"J. Virol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1172\/JCI46102","article-title":"Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients","volume":"121","author":"Baitsch","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijid.2014.05.016","article-title":"T-cell-mediated cross-strain protective immunity elicited by prime-boost vaccination with a live attenuated influenza vaccine","volume":"27","author":"Li","year":"2014","journal-title":"Int. J. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Perdiguero, B., Raman, S.C., S\u00e1nchez-Corzo, C., Sorzano, C.O.S., Valverde, J.R., Esteban, M., and G\u00f3mez, C.E. (2018). Potent HIV-1-specific CD8 T cell responses induced in mice after priming with a multiepitopic DNA-TMEP and boosting with the HIV vaccine MVA-B. Viruses, 10.","DOI":"10.3390\/v10080424"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Perdiguero, B., S\u00e1nchez-Corzo, C., Sorzano, C.O.S., Mediavilla, P., Saiz, L., Esteban, M., and G\u00f3mez, C.E. (2019). Induction of broad and polyfunctional HIV-1-specific T cell responses by the multiepitopic protein TMEP-B vectored by MVA virus. Vaccines, 7.","DOI":"10.3390\/vaccines7030057"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.eclinm.2019.05.009","article-title":"Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study)","volume":"11","author":"Mothe","year":"2019","journal-title":"EClinicalMedicine"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2020.00823","article-title":"HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02)","volume":"11","author":"Mothe","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1016\/j.vaccine.2012.04.007","article-title":"Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU\u00ae-Multi-HIVB, in untreated HIV-1 infected subjects","volume":"30","author":"Vardas","year":"2012","journal-title":"Vaccine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Buckstein","year":"2005","journal-title":"Immunity"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Muramatsu","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/CJI.0b013e3181a00068","article-title":"Direct Injection of Protamine-protected mRNA: Melanoma Patients","volume":"32","author":"Weide","year":"2009","journal-title":"J. Immunother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.clim.2009.09.009","article-title":"Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy","volume":"134","author":"Routy","year":"2010","journal-title":"Clin. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/eji.1830230749","article-title":"Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA","volume":"23","author":"Martinon","year":"1993","journal-title":"Eur. J. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1084\/jem.184.2.465","article-title":"Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo","volume":"184","author":"Boczkowski","year":"1996","journal-title":"J. Exp. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1097\/QAD.0b013e32834f33e8","article-title":"MRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients","volume":"26","author":"Vlieghe","year":"2012","journal-title":"AIDS"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"14630","DOI":"10.1038\/ncomms14630","article-title":"Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge","volume":"8","author":"Pardi","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_20","first-page":"1","article-title":"IHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy","volume":"20","author":"Aerts","year":"2019","journal-title":"Trials"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/nbt.2436","article-title":"Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection","volume":"30","author":"Petsch","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines-a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1089\/10430340150218387","article-title":"Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal\/lysosomal compartments","volume":"12","author":"Cheng","year":"2001","journal-title":"Hum. Gene Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1586\/14760584.2015.965690","article-title":"Self-replicating alphavirus RNA vaccines","volume":"14","author":"Ljungberg","year":"2014","journal-title":"Expert Rev. Vaccines"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Rna, S., Tews, B.A., and Meyers, G. (2017). Self-Replicating RNA Birke. RNA Vaccines, 1499.","DOI":"10.1007\/978-1-4939-6481-9_2"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ymthe.2019.01.020","article-title":"mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases","volume":"27","author":"Maruggi","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41541-020-0159-8","article-title":"The promise of mRNA vaccines: A biotech and industrial perspective","volume":"5","author":"Jackson","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/wrna.15","article-title":"Regulation of mRNA decapping","volume":"1","author":"Li","year":"2010","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Brito, L.A., Kommareddy, S., Maione, D., Uematsu, Y., Giovani, C., Berlanda Scorza, F., Otten, G.R., Yu, D., Mandl, C.W., and Mason, P.W. (2015). Self-Amplifying mRNA Vaccines, Elsevier Ltd.","DOI":"10.1016\/bs.adgen.2014.10.005"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/nrm.2017.103","article-title":"Functional 5\u2032 UTR mRNA structures in eukaryotic translation regulation and how to find them","volume":"19","author":"Leppek","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1128\/MCB.16.1.146","article-title":"Translational efficiency is regulated by the length of the 3\u2032 untranslated region","volume":"16","author":"Tanguay","year":"1996","journal-title":"Mol. Cell. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/nsmb.3499","article-title":"Short poly(A) tails are a conserved feature of highly expressed genes","volume":"24","author":"Lima","year":"2017","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Kudla, G., Lipinski, L., Caffin, F., Helwak, A., and Zylicz, M. (2006). High Guanine and Cytosine Content Increases mRNA Levels in Mammalian Cells. PLoS Biol., 4.","DOI":"10.1371\/journal.pbio.0040180"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Wu, G., Huang, C., and Yu, Y.T. (2015). Pseudouridine in mRNA: Incorporation, Detection, and Recoding, Elsevier Inc.. [1st ed.].","DOI":"10.1016\/bs.mie.2015.03.009"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.smim.2013.05.001","article-title":"RNA: The new revolution in nucleic acid vaccines","volume":"25","author":"Geall","year":"2013","journal-title":"Semin. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Weissman, D., Pardi, N., Muramatsu, H., and Karik\u00f3, K. (2013). HPLC Purification of In Vitro Transcribed Long RNA. Synthetic Messenger RNA and Cell Metabolism Modulation, Humana Press.","DOI":"10.1007\/978-1-62703-260-5_3"},{"key":"ref_37","first-page":"1","article-title":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA","volume":"39","author":"Muramatsu","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"10863","DOI":"10.1038\/s41598-017-11399-3","article-title":"Antibody production by in vivo RNA transfection","volume":"7","author":"Romani","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.4049\/jimmunol.165.8.4710","article-title":"HIV Gag mRNA Transfection of Dendritic Cells (DC) Delivers Encoded Antigen to MHC Class I and II Molecules, Causes DC Maturation, and Induces a Potent Human In Vitro Primary Immune Response","volume":"165","author":"Weissman","year":"2000","journal-title":"J. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.4049\/jimmunol.163.9.4721","article-title":"In vivo priming by DNA injection occurs predominantly by antigen transfer","volume":"163","author":"Corr","year":"1999","journal-title":"J. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4049\/jimmunol.179.1.329","article-title":"Potential of Transfected Muscle Cells to Contribute to DNA Vaccine Immunogenicity","volume":"179","author":"Shirota","year":"2007","journal-title":"J. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1016\/j.vaccine.2016.05.046","article-title":"Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity","volume":"34","author":"Kowalczyk","year":"2016","journal-title":"Vaccine"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.4049\/jimmunol.1502169","article-title":"RAGE Enhances TLR Responses through Binding and Internalization of RNA","volume":"197","author":"Bertheloot","year":"2016","journal-title":"J. Immunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.3109\/10717544.2015.1038856","article-title":"Induction of HIV-1 gag specific immune responses by cationic micelles mediated delivery of gag mRNA","volume":"23","author":"Zhao","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1039\/C8BM00908B","article-title":"Cationic lipid-assisted nanoparticles for delivery of mRNA cancer vaccine","volume":"6","author":"Fan","year":"2018","journal-title":"Biomater. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jconrel.2020.06.027","article-title":"Delivery of self-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic lipid selection","volume":"325","author":"Lou","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"9031","DOI":"10.1158\/0008-5472.CAN-10-0699","article-title":"Intranodal Vaccination with Naked Antigen-Encoding RNA Elicits Potent Prophylactic and Therapeutic Antitumoral Immunity","volume":"70","author":"Kreiter","year":"2010","journal-title":"Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/QAD.0000000000001276","article-title":"Preclinical evaluation of an mRNA HIV vaccine combining rationally selected antigenic sequences and adjuvant signals (HTI-TriMix)","volume":"31","author":"Guardo","year":"2017","journal-title":"Aids"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.0105-2896.2004.00139.x","article-title":"Cancer immunotherapy with mRNA-transfected dendritic cells","volume":"199","author":"Gilboa","year":"2004","journal-title":"Immunol. Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e1019197","DOI":"10.1080\/2162402X.2015.1019197","article-title":"Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients","volume":"4","author":"Bol","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1099\/vir.0.80907-0","article-title":"Identification of classical swine fever virus protein E2 as a target for cytotoxic T cells by using mRNA-transfected antigen-presenting cells","volume":"86","author":"Ceppi","year":"2005","journal-title":"J. Gen. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00262-012-1334-1","article-title":"Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation","volume":"62","author":"Hobo","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1002\/eji.200636782","article-title":"Robust CD4+ and CD8+ T cell responses to SIV using mRNA-transfected DC expressing autologous viral Ag","volume":"37","author":"Melhem","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1002\/eji.201242478","article-title":"CD34-derived dendritic cells transfected ex vivo with HIV-Gag mRNA induce polyfunctional T-cell responses in nonhuman primates","volume":"42","author":"Romain","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jconrel.2016.02.043","article-title":"Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra-and paracellular pathways","volume":"228","author":"Li","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Udhayakumar, V.K., De Beuckelaer, A., McCaffrey, J., McCrudden, C.M., Kirschman, J.L., Vanover, D., Van Hoecke, L., Roose, K., Deswarte, K., and De Geest, B.G. (2017). Arginine-Rich Peptide-Based mRNA Nanocomplexes Efficiently Instigate Cytotoxic T Cell Immunity Dependent on the Amphipathic Organization of the Peptide. Adv. Healthc. Mater., 6.","DOI":"10.1002\/adhm.201601412"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Persano, S., Guevara, M.L., Li, Z., Mai, J., Ferrari, M., Pompa, P.P., and Shen, H. (2017). Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination. Biomaterials, 125.","DOI":"10.1016\/j.biomaterials.2017.02.019"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Reichmuth, A.M., Oberli, M.A., Jaklenec, A., Langer, R., and Blankschtein, D. (2016). mRNA vaccine delivery using lipid nanoparticles. Ther. Deliv., 7.","DOI":"10.4155\/tde-2016-0006"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Semple, S.C., Akinc, A., Chen, J., Sandhu, A.P., Mui, B.L., Cho, C.K., Sah, D.W.Y., Stebbing, D., Crosley, E.J., and Yaworski, E. (2010). Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol., 28.","DOI":"10.1038\/nbt.1602"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Hassett, K.J., Benenato, K.E., Jacquinet, E., Lee, A., Woods, A., Yuzhakov, O., Himansu, S., Deterling, J., Geilich, B.M., and Ketova, T. (2019). Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines. Mol. Ther. Nucleic Acids, 15.","DOI":"10.1016\/j.omtn.2019.01.013"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Lutz, J., Lazzaro, S., Habbeddine, M., Schmidt, K.E., Baumhof, P., Mui, B.L., Tam, Y.K., Madden, T.D., Hope, M.J., and Heidenreich, R. (2017). Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines. NPJ Vaccines, 2.","DOI":"10.1038\/s41541-017-0032-6"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Jayaraman, M., Ansell, S.M., Mui, B.L., Tam, Y.K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., and Narayanannair, J.K. (2012). Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo. Angew. Chem. Int. Ed., 51.","DOI":"10.1002\/anie.201203263"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Pardi, N., LaBranche, C.C., Ferrari, G., Cain, D.W., Tomb\u00e1cz, I., Parks, R.J., Muramatsu, H., Mui, B.L., Tam, Y.K., and Karik\u00f3, K. (2019). Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques. Mol. Ther. Nucleic Acids, 15.","DOI":"10.1016\/j.omtn.2019.03.003"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Guevara, M.L., Jilesen, Z., Stojdl, D., and Persano, S. (2019). Codelivery of mRNA with \u03b1-Galactosylceramide Using a New Lipopolyplex Formulation Induces a Strong Antitumor Response upon Intravenous Administration. ACS Omega, 4.","DOI":"10.1021\/acsomega.9b00489"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Tan, L., Zheng, T., Li, M., Zhong, X., Tang, Y., Qin, M., and Sun, X. (2020). Optimization of an mRNA vaccine assisted with cyclodextrin-polyethyleneimine conjugates. Drug Deliv. Transl. Res., 10.","DOI":"10.1007\/s13346-020-00725-4"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Mai, Y., Guo, J., Zhao, Y., Ma, S., Hou, Y., and Yang, J. (2020). Intranasal delivery of cationic liposome-protamine complex mRNA vaccine elicits effective anti-tumor immunity. Cell. Immunol., 354.","DOI":"10.1016\/j.cellimm.2020.104143"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Moyo, N., Vogel, A.B., Buus, S., Erbar, S., Wee, E.G., Sahin, U., and Hanke, T. (2019). Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA. Mol. Ther. Methods Clin. Dev., 12.","DOI":"10.1016\/j.omtm.2018.10.010"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/14760584.2017.1322513","article-title":"New challenges in therapeutic vaccines against HIV infection","volume":"16","author":"Leal","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/S2352-3018(20)30232-0","article-title":"The case for an HIV cure and how to get there","volume":"8","author":"Dybul","year":"2021","journal-title":"Lancet HIV"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/QAD.0b013e328344cea5","article-title":"A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune","volume":"25","author":"Angel","year":"2011","journal-title":"AIDS"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1128\/CVI.13.1.26-32.2006","article-title":"Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1","volume":"13","author":"Gorse","year":"2006","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Dinges, W., Girard, P.M., Podzamczer, D., Brockmeyer, N.H., Garc\u00eda, F., Harrer, T., Lelievre, J.D., Frank, I., De Verdi\u00e8re, N.C., and Yeni, G.P. (2016). The F4\/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, but Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial. Medicine, 95.","DOI":"10.1097\/MD.0000000000002673"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1097\/01.aids.0000180104.65640.16","article-title":"Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: Safety and immunogenicity of an HIV-1 gag\/poly-epitope DNA vaccine","volume":"19","author":"Dorrell","year":"2005","journal-title":"AIDS"},{"key":"ref_74","first-page":"166ra2","article-title":"A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication","volume":"5","author":"Climent","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/QAD.0b013e328340fe55","article-title":"Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine","volume":"25","author":"Papagno","year":"2011","journal-title":"AIDS"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/QAI.0000000000000926","article-title":"Dendritic cell immunotherapy for HIV-1 infection using autologous HIV-1 RNA: A randomized, double-blind, placebo-controlled clinical trial","volume":"72","author":"Jacobson","year":"2016","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/aid.2017.0071","article-title":"Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated during Acute HIV Infection","volume":"34","author":"Gay","year":"2018","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"5134","DOI":"10.1038\/s41598-020-61878-3","article-title":"Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection","volume":"10","author":"Gay","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/QAI.0000000000000852","article-title":"Immunization of HIV-1-infected persons with autologous dendritic cells transfected with mRNA encoding HIV-1 Gag and Nef: Results of a randomized, placebo-controlled clinical trial","volume":"71","author":"Gandhi","year":"2016","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"de Jong, W., Leal, L., Buyze, J., Pannus, P., Guardo, A., Salgado, M., Mothe, B., Molto, J., Moron-Lopez, S., and G\u00e1lvez, C. (2019). Therapeutic vaccine in chronically Hiv-1-infected patients: A randomized, double-blind, placebocontrolled phase IIa trial with HTI-Trimix. Vaccines, 9.","DOI":"10.3390\/vaccines7040209"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1097\/QAD.0000000000002026","article-title":"Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection","volume":"32","author":"Leal","year":"2018","journal-title":"AIDS"},{"key":"ref_82","unstructured":"(2019). Erratum: Preclinical evaluation of an mRNA HIV vaccine combining rationally selected antigenic sequences and adjuvant signals (HTI-TriMix): Erratum Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infecti. AIDS."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Wadhwa, A., Aljabbari, A., Lokras, A., Foged, C., and Thakur, A. (2020). Opportunities and Challenges in the Delivery of mRNA-Based Vaccines. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12020102"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Pardi, N., and Weissman, D. (2017). Nucleoside Modified mRNA Vaccines for Infectious Diseases. RNA Vaccines, Humana Press.","DOI":"10.1007\/978-1-4939-6481-9_6"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1084\/jem.20171450","article-title":"Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses","volume":"215","author":"Pardi","year":"2018","journal-title":"J. Exp. Med."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Xu, S., Yang, K., Li, R., and Zhang, L. (2020). mRNA Vaccine Era\u2014Mechanisms, Drug Platform and Clinical Prospection. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186582"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-016-1111-6","article-title":"Adjuvant effects of a sequence-engineered mRNA vaccine: Translational profiling demonstrates similar human and murine innate response","volume":"15","author":"Edwards","year":"2017","journal-title":"J. Transl. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Baden, L.R., El Sahly, H.M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S.A., Rouphael, N., and Creech, C.B. (2020). Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med., NEJMoa2035389.","DOI":"10.1056\/NEJMoa2035389"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.chom.2020.03.014","article-title":"The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies","volume":"27","author":"Cohn","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nm.4108","article-title":"International AIDS Society global scientific strategy: Towards an HIV cure 2016","volume":"22","author":"Deeks","year":"2016","journal-title":"Nat. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40265-020-01322-y","article-title":"Novel Approaches Towards a Functional Cure of HIV\/AIDS","volume":"80","author":"Bailon","year":"2020","journal-title":"Drugs"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/ni.3543","article-title":"CXCR5+ follicular cytotoxic T cells control viral infection in B cell follicles","volume":"17","author":"Leong","year":"2016","journal-title":"Nat. Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/gt.2013.80","article-title":"Interference with PD-L1\/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells","volume":"21","author":"Pen","year":"2014","journal-title":"Gene Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature18929","article-title":"HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"McMahon, D.K., Zheng, L., Cyktor, J.C., Aga, E., Macatangay, B.J., Godfrey, C., Para, M., Mitsuyasu, R.T., Hesselgesser, J., and Dragavon, J. (2020). A phase I\/II randomized, placebo-controlled trial of romidepsin in persons with HIV-1 on suppressive antiretroviral therapy to assess safety and activation of HIV-1 expression (A5315). J. Infect. Dis.","DOI":"10.1093\/infdis\/jiaa777"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/3\/501\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:37:45Z","timestamp":1760161065000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/13\/3\/501"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,18]]},"references-count":96,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["v13030501"],"URL":"https:\/\/doi.org\/10.3390\/v13030501","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,18]]}}}